Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid

Abstract EN

Objective.

The objective of this analysis was to compare clinical and cost outcomes associated with patients who had suspected or documented methicillin-resistant Staphylococcus aureus (MRSA) infections treated with daptomycin, vancomycin, or linezolid in complicated skin and skin structure infections (cSSSIs).

Design.

This was a retrospective analysis conducted from February to June of 2007.

Appropriate data was collected, collated, and subsequently evaluated with the purpose of quantifying length of stay, antibiotic therapy duration, clinical cure rates, adverse drug events, and cost of hospitalization.

Results.

All 82 patients included in the analysis experienced clinical cure.

The duration of antibiotic therapy was similar among the three groups yet the length of hospitalization was slightly shorter in the daptomycin group.

Conclusions.

The incidence of resistant staphylococcal infections is increasing; therefore, judicious use of MRSA active agents is paramount.

Future studies are necessary to determine if MRSA treatment options can be stratified based on the severity of the infectious process.